2016
DOI: 10.1016/j.jacc.2016.03.475
|View full text |Cite|
|
Sign up to set email alerts
|

Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics

Abstract: The BuMA SES was demonstrated to be noninferior to the Excel SES for 1-year TLF, with a lower incidence of stent thrombosis. (Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "Real-World" Practice [PANDA-III]; NCT02017275).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
36
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 44 publications
(36 citation statements)
references
References 17 publications
0
36
0
Order By: Relevance
“…Acute thrombogenicity and long-term vascular healing in DES has been attributed, not only to drug pharmacokinetics, durable polymer biocompatibility, composition distribution, and, in case of BP-DES, duration of bioresorption, but also to the platform material and stent strut thickness. [30][31][32] Indeed, compared with the thicker struts, thinner strut platforms have been shown to reduce platelet aggregation and inflammatory cell adhesion. 33,34 The BP-EES evaluated in this study was designed to facilitate stent vascular healing using a thinner strut profile (71 μm) when compared to DP-EES (81 μm).…”
Section: Discussionmentioning
confidence: 99%
“…Acute thrombogenicity and long-term vascular healing in DES has been attributed, not only to drug pharmacokinetics, durable polymer biocompatibility, composition distribution, and, in case of BP-DES, duration of bioresorption, but also to the platform material and stent strut thickness. [30][31][32] Indeed, compared with the thicker struts, thinner strut platforms have been shown to reduce platelet aggregation and inflammatory cell adhesion. 33,34 The BP-EES evaluated in this study was designed to facilitate stent vascular healing using a thinner strut profile (71 μm) when compared to DP-EES (81 μm).…”
Section: Discussionmentioning
confidence: 99%
“…The trial design was previously described . Briefly, the PANDA III (ClinicalTrials.gov identifier: NCT02017275) was a prospective, randomized controlled trial conducted between December 2013 to August 2014, in which 2,348 patients with chronic, stable ischemic heart disease or acute coronary syndromes, including AMI with or without ST‐segment elevation, were assigned in a 1:1 treatment allocation to receive either BuMA SES or Excel SES.…”
Section: Methodsmentioning
confidence: 99%
“…Secondary endpoints included the patient‐oriented composite endpoint (PoCE) of all‐cause death, all MI, or any revascularization; the individual components of TLF, PoCE; and stent thrombosis (ST), defined according to definite or probable Academic Research Consortium criteria. Detailed definitions of endpoints have been previously reported .…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The BuMA and EXCEL stents were then compared in the larger, all-comers multicenter PANDA III trial (NCT02017275) [102]. A total of 2,348 patients were enrolled and randomized (1:1, n=1,174 in each arm); the primary endpoint of 1 year TLF (cardiac death, TV-MI, ID-TLR) with BuMA was noninferior to the EXCEL stent (6.4% in each group, P noninferiority =0.0003).…”
Section: Clinical Trials Of Bioabsorbable Polymer-coated Desmentioning
confidence: 99%